Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec

J. Agulnik MD,*, G. Kasymjanova MD,*, C. Pepe MD,*, M. Hurry MSc, MSc†, R.N. Walton MPH,†
L. Sakr MD,*, V. Cohen MD,*, M. Lecavalier MD,*, and D. Small MD*

INTRODUCTION

In 2020, 8600 Quebecers are expected to be diagnosed with lung cancer. Lung cancer is also expected to be the leading cause of cancer death, accounting for 25.5% of all cancer deaths in Quebec1,2. The 5-year overall survival (OS) of patients with lung cancer varies by stage. Patients diagnosed at earlier stages of disease experience longer survival than those diagnosed at more advanced stages, with 5-year OS rates being as high as 73% for patients with stage Ia lung cancer and as low as 2% for those with stage IV disease3. Stage III NSCLC is highly heterogeneous, with disease presentations ranging from resectable tumours with occult microscopic nodal metastases to tumours that are...
non-operable, with a large burden of nodal involvement1,5. The incidence of stage III lung cancer in Canada ranges from 13.5 cases per 100,000 individuals in Alberta to 20.3 cases per 100,000 individuals in New Brunswick6. Population-based data collected from 1995 to 2007 in Alberta and Manitoba showed that, of the more than 8000 patients with NSCLC, 26.4% had stage III disease2. The prognosis in stage III NSCLC is poor: 5-year OS is 19%–24% for stage IIIA NSCLC and 7%–9% for stage IIIB NSCLC3. Similar information is not available for the province of Quebec.

Treatment in this setting has been limited to concurrent chemotherapy and radiation, an approach that has remained unchanged for more than a decade9. Despite treatment being curative, 5-year survival remains poor, being limited to 9%–12% of patients treated with combined chemoradiotherapy (CRT)10.

Recently, based on results in the PACIFIC trial (see NCT02125461 at https://ClinicalTrials.gov/), Health Canada approved durvalumab for patients with unresectable stage III NSCLC. The PACIFIC trial demonstrated a statistically significant improvement in progression-free survival (PFS) and OS11–13. However, real-world data about treatment patterns and clinical outcomes for stage III NSCLC in Canada are limited.

The objective of the present study was to describe treatment patterns and survival, and to assess clinical factors affecting survival in patients with unresectable stage III NSCLC treated at a single academic centre in the province of Quebec over the last 12 years. Our study aimed to contextualize the effect of the PACIFIC trial with real-world experience.

METHODS

Study Design

This retrospective cohort study considered patients diagnosed with stage III NSCLC at the Sir Mortimer B. Davis Jewish General Hospital in Montreal, Quebec. Data were extracted from a clinical database that contains clinical, demographic, treatment, and survival information for cases of lung cancer diagnosed between 1998 and 2018. The lung cancer registry was approved by the institutional review board.

The database created in 2001 uses the Access software application (Microsoft Corporation, Redmond, WA, U.S.A.) and contains multiple tables connected by a primary key. Variables captured include demographics, past medical history, diagnostic tests, disease stage, molecular tests, surgery, timelines and treatment plan, chemotherapy, radiation therapy (RT), imaging, and outcomes.

The long-term goals of creating the database are quality assurance and clinical research that contributes information to the fight against lung cancer (for example, to develop better tests and therapies for lung cancer). The short-term goal is to improve the understanding and predict the outcomes of individual treatments by compiling routine clinical information.

As a routine practice, every patient diagnosed with lung cancer is presented to a multidisciplinary tumour board for staging and treatment plan discussion. Each case is entered into the database in real time by a data manager at the first tumour board presentation. Cases might be re-presented if outcome or treatment changes (or both) occur. Information is updated in the database at each presentation. The final update takes place after the death of the patient and before the patient’s chart is archived.

Patients Selection Criteria

Patients were included if they were 18 years of age or older, had a histologically confirmed diagnosis of NSCLC, and were staged clinically or pathologically as stage III according to the 7th edition of the TNM classification. All patients meeting these criteria were included.

To ensure sufficient maturity of survival data and homogeneity of treatment, only patients diagnosed from January 2007 to May 2018 were analyzed for the study. The database was locked for analysis at 31 August 2018.

Statistical Analysis

Summary statistics are used to describe patient demographics, disease-related characteristics, treatment patterns, and occurrence of adverse events. Means with standard deviation are reported for continuous variables, and frequencies and percentages are reported for categorical variables such as

- patient demographics (age, sex, ethnicity or race, smoking status),
- disease-related characteristics (stage at primary diagnosis, Eastern Cooperative Oncology Group performance status (ECOG PS), histology, size of tumour, nodal involvement, and mutation status),
- treatment patterns (concurrent CRT (cCRT) and sequential CRT (sCRT)).

These outcome variables were defined:

- Overall survival—the time elapsed from the start of RT to the date of death or last follow-up (all patients)
  To align with the PACIFIC trial, an exploratory analysis was carried out to determine OS from the end of RT. To determine disease-specific survival, patients who died of causes unrelated to lung cancer were excluded. Overall survival was also calculated for patients who would have been eligible for durvalumab if it had been available at the time. Patients were considered eligible if they had completed CRT, had not progressed within 14 days of the end of therapy, were not receiving steroids at 10 mg or more daily, and had a good PS.
- Progression-free survival—the time elapsed from the start of RT to the date of progression (progression was determined based on radiologic imaging and response as assessed by the treating physician).

Survival was analyzed using the log-rank test and the Kaplan–Meier method to determine median OS and the associated 95% confidence interval. A Cox proportional hazards model was used to identify factors prognostic for survival. The factors included in the multivariate forward conditional model were age, sex, smoking status, ECOG PS,
histology, treatment pattern, tumour size, and nodal status.

Statistical analyses were conducted using the IBM SPSS Statistics software application (version 20: IBM, Armonk, NY, U.S.A.) for Windows (Microsoft Corporation).

**RESULTS**

**Patient Characteristics**

From January 2007 until May 2018, 263 patients were diagnosed with stage III NSCLC; 37 (14%) underwent surgery, and 226 (86%) were deemed to have unresectable disease and were included for analysis. Of those 226 patients, 92 (41%) received either definitive radiation, systemic chemotherapy, or best supportive care (Figure 1). The remaining 134 (59%) were treated with combined CRT. Of those 134 patients, 114 (85%) were treated with cCRT, and 20 (15%), with sCRT.

Mean age of the patients was 65 ± 9.8 years; most were white and ex-smokers or current smokers, and they had an ECOG PS of 0 or 1 and nonsquamous histology. The baseline characteristics of patients treated with cCRT and sCRT were different: the former group were significantly younger and showed a slight prevalence of nonsquamous histology and mostly N1 or single-station N2 disease (Table 1). A mediastinal staging procedure was performed in 96 patients from that group (72%), and positron-emission tomography imaging for staging was performed in 93 (69%). The tumour was graded in 75% of cases: well differentiated in 23 (17%), moderately differentiated in 18 (13%), poorly differentiated in 14 (10%), and undifferentiated in 5 (4%).

These chemotherapy regimens were used:

- Cisplatin–etoposide (modified SWOG protocol)\(^\text{14}\): intravenous (IV) cisplatin 50 mg/m\(^2\) on days 1, 8, 29, and 36 with IV etoposide 50 mg/m\(^2\) on days 1–5 and 29–33. The RT was started on day 2 of chemotherapy at 1.8 Gy daily 5 days per week for a total of 25 fractions (45 Gy) to the primary and mediastinum, followed by a boost to the primary and involved nodes of 1.8 Gy daily for up to 8 fractions (15 Gy). The total dose of RT was 60–66 Gy in 30–33 fractions. This modified SWOG protocol was used in 43 patients (32.1%) receiving cCRT treatment.

- Induction chemotherapy followed by CRT\(^\text{15}\): induction used 2 cycles of carboplatin–gemcitabine in a 21-day regimen (IV carboplatin 5 AUC (area under the curve) given over 30 minutes on day 1, and IV gemcitabine 1000 mg/m\(^2\) given over 30 minutes on days 1 and 8). The CRT started after the induction chemotherapy and consisted of IV paclitaxel 50 mg/m\(^2\) given over 60 minutes on days 1 and 8 and IV gemcitabine 100 mg/m\(^2\) given over 30 minutes on days 1 and 8 of each 3-week cycle for 2 cycles. The RT was given at a total tumour dose of 60–66 Gy over 6 weeks, starting with day 1 of chemotherapy cycle 3. This regimen is approved as the standard treatment for stage III NSCLC treatment in Quebec. Two cycles of full-dose induction chemotherapy followed by CRT was used in 50 patients (37.3%).

- Randomized controlled trials with platinum-based chemotherapy and concurrent RT: chemotherapy according to randomized controlled trial protocol was used in 11 patients (8.2%).

- Other platinum-based chemotherapy regimens, such as carboplatin–pemetrexed and carboplatin–gemcitabine given with RT with curative intent: one of those chemotherapy regimens with RT was used in 30 patients (22.4%).

**Patients Potentially Eligible for Maintenance Durvalumab**

After completing initial curative treatment, the 134 patients were followed by their treating pulmonary oncologist every 2–3 months with radiographic imaging. Of those patients, 104 (77.6%) would have been eligible for durvalumab consolidation therapy, and the remaining 30 (22.4%) would have been excluded for these reasons:

- Prematurely stopped radiation therapy (5 patients)
- Progressed within 14 days of ending RT (4 patients)
- Treated with steroids at 10 mg or more daily for treatment complications (15 patients)
- Had a poor ECOG PS (6 patients)

**Treatment After Progression**

After initial treatment, 86 of the 134 patients (64.2%) had progressed and received subsequent therapy. Most were treated with subsequent chemotherapy (57%). Immunotherapies or targeted therapies were used as treatment in 22 patients (26%, Table II).

**PFS and OS**

At the time of analysis, mean duration of follow-up was 32 months (range: 2–138 months), with 92 deaths (68.7%) and 86 (64%) progression events having been observed. The PFS was slightly better for patients treated concurrently than for those treated sequentially (Figure 2). Median PFS was 7.97 months for cCRT compared with 5.26 months for sCRT, but the difference was not statistically significant (\(p = 0.081\)).

Median OS was significantly better for cCRT than for sCRT, whether assessed from the start (Figure 3) or end of RT (Figure 4). The disease-specific survival calculation excluded 14 patients because of death from causes other than lung cancer. The OS in the cCRT group remained significant at \(p = 0.004\) (Figure 5).
| Variable | Stage III unresectable | Stage III treated with CRT | p Value\(^a\) |
|----------|------------------------|----------------------------|---------------|
| Patients (n) | 226 | 134 | 114 | 20 |
| Age (years) | | | | 0.003 |
| Mean | 66±10.7 | 65±9.8 | 64.3±9.5 | 70.4±9.2 |
| Range | 31–88 | 31–82 | 31–81 | 50–82 |
| Sex | | | | 0.41 |
| Women | 106 (47.0) | 67 (50.0) | 58 (51.0) | 9 (45.0) |
| Men | 120 (53.0) | 67 (50.0) | 56 (49.0) | 11 (55.0) |
| Ethnicity | | | | 0.73 |
| White | 203 (90.0) | 118 (88.1) | 99 (86.8) | 19 (95.0) |
| Asian | 16 (7.1) | 11 (8.2) | 10 (8.8) | 1 (5.0) |
| Other | 7 (2.9) | 5 (3.7) | 5 (4.4) | 0 (0.0) |
| Smoking status\(^b\) | | | | 0.34 |
| Current smoker | 121 (53.5) | 70 (52.0) | 63 (55.3) | 10 (50.0) |
| Ex-smoker | 80 (35.4) | 52 (39.0) | 40 (35.1) | 9 (45.0) |
| Never-smoker | 20 (11.1) | 12 (9.0) | 11 (9.6) | 1 (5.0) |
| ECOG PS\(^b\) | | | | 0.76 |
| 0 | 72 (32.0) | 42 (31.3) | 37 (32.5) | 5 (25.0) |
| 1 | 140 (61.9) | 84 (62.7) | 70 (61.4) | 14 (70.0) |
| 2 | 14 (6.1) | 8 (6.0) | 7 (6.1) | 1 (5.0) |
| Stage (TNM) | | | | 0.17 |
| IIIA | 120 (69.0) | 99 (73.9) | 87 (76.3) | 12 (60.0) |
| IIIB | 106 (31.0) | 35 (26.1) | 27 (23.7) | 8 (40.0) |
| Primary tumour size | | | | 0.84 |
| ≤3 cm | 53 (23.6) | 46 (34.3) | 40 (35.1) | 6 (30.0) |
| >3 cm and ≤5 cm | 83 (36.7) | 40 (29.9) | 33 (28.9) | 7 (35.0) |
| >5 cm | 90 (39.7) | 48 (35.8) | 41 (36) | 7 (35.0) |
| Histology | | | | 0.09 |
| Non-squamous | 144 (63.5) | 108 (80.6) | 93 (81.6) | 16 (65.0) |
| Squamous | 82 (36.5) | 36 (24.4) | 21 (18.4) | 7 (35.0) |
| N Stage | | | | <0.001 |
| N1/N2, single station | 99 (43.8) | 97 (72.4) | 97 (85) | 0 (0) |
| N2, multi-station, or N3 | 127 (56.2) | 37 (27.6) | 17 (15) | 20 (100.0) |
| Mediastinal staging | | | | 0.96 |
| EBUS or EUS | 62 (27.0) | 43 (32.0) | 37 (32.0) | 6 (30.0) |
| TBNA | 73 (32.0) | 32 (24.0) | 27 (24.0) | 6 (30.0) |
| MED | 23 (10.0) | 21 (16.0) | 17 (15.0) | 5 (25.0) |
| Not done | 68 (30.0) | 38 (28.0) | 33 (29.0) | 3 (15.0) |
| Grade | | | | 0.78 |
| 1 | 45 (20.0) | 21 (16.0) | 18 (16.0) | 3 (15.0) |
| 2 | 29 (13.0) | 18 (13.0) | 15 (13.0) | 3 (15.0) |
| 3 | 86 (38.0) | 54 (40.0) | 50 (44.0) | 4 (20.0) |
| 4 | 11 (5.0) | 6 (4.0) | 2 (1.7) | 4 (20.0) |
| Not done | 55 (25.0) | 35 (27.0) | 29 (25.3) | 6 (30.0) |
| PET imaging | | | | 0.08 |
| Yes | 152 (67.0) | 93 (69.0) | 82 (72) | 11 (55.0) |
| No | 74 (33.0) | 41 (31.0) | 32 (28) | 9 (45.0) |
| Subsequent therapy | | | | 0.83 |
| Yes | 118 (52.2) | 86 (64.2) | 71 (62.3) | 15 (75.0) |
| No | 108 (47.8) | 48 (35.8) | 15 (75.0) | 5 (25.0) |

\(^{a}\) Comparing concurrent with sequential CRT. Boldface type indicates a significant difference.

\(^{b}\) Data missing for 5 patients.

CRT = chemoradiotherapy; ECOG PS = Eastern Cooperative Oncology Group performance status; EBUS = endobronchial ultrasonography; EUS = endoscopic ultrasonography; TBNA = transbronchial needle aspiration; MED = mediastinoscopy; PET = positron-emission tomography.
TABLE II  Subsequent treatments after first-line treatment

| Treatment                        | Patients [n (%)] |
|----------------------------------|------------------|
| Chemotherapy alone               | 49 (57.0)        |
| Radiotherapy alone (palliative)  | 15 (17.4)        |
| Immunotherapy                    | 13 (15.1)        |
| Targeted therapy                 | 9 (10.5)         |

FIGURE 2 Progression-free survival by type of combined treatment: concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy from the start of radiotherapy (sCRT).

| Treatment | Median (mo) | 95% confidence interval |
|-----------|-------------|-------------------------|
| cCRT      | 7.567       | 4.734 - 11.184          |
| sCRT      | 5.267       | 4.056 - 6.477           |
| Overall   | 7.033       | 5.565 - 8.502           |

Log Rank (Mantel-Cox) = 0.081

FIGURE 3 Overall survival of patients from the start of radiotherapy (RT), by the type of combined treatment: concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy from the start of radiotherapy (sCRT).

| Treatment | Median (mo) | 95% confidence interval |
|-----------|-------------|-------------------------|
| cCRT      | 23.267      | 14.795 - 32.239         |
| sCRT      | 11.333      | 10.165 - 12.502         |
| Overall   | 18.567      | 12.357 - 24.776         |

Log Rank (Mantel-Cox) = 0.014

FIGURE 4 Overall survival of patients from the end of radiotherapy (RT), by the type of combined treatment: concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy from the start of radiotherapy (sCRT).

| Treatment | Median (mo) | 95% confidence interval |
|-----------|-------------|-------------------------|
| cCRT      | 21.733      | 12.815 - 30.652         |
| sCRT      | 9.667       | 8.206 - 11.128          |
| Overall   | 17.100      | 10.812 - 23.388         |

Log Rank (Mantel-Cox) = 0.014

FIGURE 5 Disease-specific survival from the start of radiotherapy (RT), by the type of combined treatment: concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy from the start of radiotherapy (sCRT).

Table III shows the results of univariate analyses of survival that included sex, age, smoking status, ECOG PS, histology, type of CRT, size of the tumour, and nodal status. Superior survival was associated with N1 or single-station N2 involvement, a tumour size of 3 cm or less, and being treated with cCRT. Median OS was 28.6 months (95% confidence interval: 18.5 months to 38.6 months) for patients with N1 or single-station N2 involvement (Figure 6). A trend toward survival benefit was observed in patients with nonsquamous histology and female sex.
The multivariate analysis of survival demonstrated that tumour size and nodal station involvement were the only factors predictive of survival in patients treated with CRT (Table III).

In patients who would have been eligible for treatment with durvalumab according to the PACIFIC trial criteria (n = 104), median OS was 21.9 months (95% confidence interval: 12.3 months to 31.4 months).

**TABLE III**  Cox regression analyses of overall survival in 134 patients receiving chemoradiotherapy (CRT)

| Variable                | Comparator     | Univariate analysis | Multivariate analysis | Exp(B)     | 95% CI       | p Value | Exp(B)     | 95% CI       | p Value |
|-------------------------|----------------|---------------------|-----------------------|------------|--------------|---------|------------|--------------|---------|
| Female                  | Male           |                     |                       | 0.67       | 0.44 to 1.00 | 0.052   | 1.19       | 0.76 to 1.85 | 0.44    |
| Age ≤65                 | >65            |                     |                       | 1.35       | 0.89 to 2.03 | 1.47    | 1.26       | 0.80 to 2.00 | 0.31    |
| Ever-smoker             | Never-smoker   |                     |                       | 1.23       | 0.57 to 2.67 | 0.59    | 0.89       | 0.40 to 1.97 | 0.78    |
| ECOG PS ≤2              | >2             |                     |                       | 0.86       | 0.43 to 2.02 | 0.86    | 1.20       | 0.54 to 2.67 | 0.65    |
| Nonsquamous             | Squamous       |                     |                       | 1.64       | 0.99 to 2.71 | 0.053   | 0.76       | 0.45 to 1.29 | 0.32    |
| cCRT                    | sCRT           |                     |                       | 1.94       | 1.15 to 3.25 | 0.01    | 0.69       | 0.32 to 1.49 | 0.35    |
| Tumour ≤3 cm            | >3 cm          |                     |                       | 1.80       | 1.15 to 2.83 | 0.01    | 0.63       | 0.39 to 1.00 | 0.05    |
| N1/N2, single-station   | N2, multi-station, or N3 |     |                       | 2.26       | 1.46 to 3.52 | <0.001  | 0.39       | 0.21 to 0.74 | <0.004  |

CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; cCRT = concurrent CRT; sCRT = sequential CRT.

**FIGURE 6** Overall survival of patients with N1/N2 single-station nodal involvement compared with N2 multi-station or N3 nodal involvement from the start of radiotherapy (RT).

The multivariate analysis of survival demonstrated that tumour size and nodal station involvement were the only factors predictive of survival in patients treated with CRT (Table III).

In patients who would have been eligible for treatment with durvalumab according to the PACIFIC trial criteria (n = 104), median OS was 21.9 months (95% confidence interval: 12.3 months to 31.4 months).

**TABLE IV**  Reasons for emergency room visits

| Reason                  | Patients |
|-------------------------|----------|
| (n)                     | (%)      |
| Radiation pneumonitis   | 12       | 25       |
| Infections              |          |          |
| Pulmonary (pneumonia)   | 9        | 18.7     |
| Others (abscess, cellulitis, endocarditis) | 4 | 8.0 |
| Fatigue                 | 6        | 12.4     |
| Pain                    | 5        | 10.4     |
| Radiation esophagitis   | 3        | 6.2      |
| PE or DVT               | 3        | 6.2      |
| Febrile neutropenia     | 3        | 6.2      |
| Pleural effusion        | 3        | 6.2      |
| TOTAL                   | 48       | 100.0    |

PE = pulmonary embolism; DVT = deep vein thrombosis.

Complications was not different for concurrent (22%) and sequential (20%) treatment.

**DISCUSSION**

The results of this observational study provide a description of treatment patterns in an academic centre and reveal that the treatment of unresectable stage III NSCLC in general was in line with guidelines\(^{16,17}\). To our knowledge, the present report is the first of a real-world experience from Quebec. According to the Canadian Cancer Registry, the incidence of stage III cancer ranges from 13% to 23% in various provinces\(^{18}\). Approximately 88% of patients with stage III NSCLC present with disease that is not amenable to curative resection\(^{19}\), similar to the rate seen in our study population. The Canadian Cancer Society team recommends the use of CRT for patients with inoperable stage III disease, a good performance status (ECOG 0–2), minimal weight loss, good pulmonary reserve, and tumour and anatomic confirmation, permitting radical-dose radiation without expected severe normal-tissue toxicity\(^{18,20}\). Curative-intent CRT was
given to 59% of the patients with unresectable stage III NSCLC in our study, which is similar to data from Cancer Care Ontario. From 2010 to 2013 in Ontario, 48% of patients with inoperable lung cancer received curative-intent combined CRT, with a regional variation of 31%–63%. Our results revealed that median OS in patients treated with combined CRT was 18.6 months. Based on the log-rank test, a significant survival benefit accrued to patients treated using CRT compared with SCRT. That survival benefit of CRT over SCRT observed in univariate analysis was no longer present in the multivariate analyses. The most probable explanation for the loss of significance is selection bias: patients receiving CRT were younger, with less bulky disease. This type of bias occurs often in retrospective cohort studies and is usually controlled with Cox regression analysis.

The West Japan Lung Cancer Group and Radiation Therapy Oncology Group 941028 studies both compared CRT with SCRT. Both trials demonstrated modest survival improvements in favour of CRT. Auperin et al. observed a significant benefit of CRT (hazard ratio: 0.84; \( p = 0.004 \)) compared with SCRT. However, in all of the foregoing studies, the survival benefit came at the expense of higher treatment toxicity, which was reported to be almost a 3–4 times that with sequential therapy. Our study failed to demonstrate the higher rate of toxicity in the CRT group compared with the SCRT group, possibly because 37% of the CRT group received gemcitabine–paclitaxel chemotherapy concurrent with radiation after 2 cycles of platinum-based induction therapy, which is the accepted chemotherapy regimen in Quebec. According to the latest guidelines from the American Society for Radiation Oncology, the optimal chemotherapy regimen for combined CRT is not known, given a paucity of randomized trials comparing various chemotherapy regimens in the setting of locally-advanced NSCLC. The most commonly used regimens are combined cisplatin–etoposide and weekly carboplatin–paclitaxel. More recently, pemetrexed–cisplatin has been more prevalent in patients with nonsquamous NSCLC.

A small proportion of our patients (10%) died from causes other than lung cancer, which is consistent with the 14% reported by Souza et al. Disease-specific survival was better when those patients were excluded.

Of our patients with unresectable stage III NSCLC, 78% would have been eligible to receive consolidation therapy with durvalumab, which is similar to the 70% reported by Sakaguchi et al. Those patients had an OS of 21.9 months compared with 18.6 months for the cohort overall. Based on Cox regression analysis, the number of involved lymph nodes and the size of the primary tumour significantly affected survival. Combined CRT has the potential to offer patients with N1 or single-station N2 disease and a smaller primary tumour the combined benefits of improved local and distant disease control.

As in any retrospective cohort study, eliminating the possibility of selection bias is challenging. However, it appears that our study cohort is representative of the entire population of patients with unresectable stage III NSCLC treated at our institution. The study relies on data already collected, and therefore any systematic errors occurring during the chart abstraction process cannot be captured.

The 7th edition of the TNM staging system was used in our study. That system excludes patients with stage II disease who would have migrated to stage III under the 8th edition of TNM staging. Another limitation of the study would be the lack of positron-emission tomography imaging, proper mediastinal staging at the time of diagnosis, and tumour differentiation (grade). Novel treatments such checkpoint inhibitors or durvalumab maintenance therapy were not available at the time of the study. Also, the study was limited to a single centre in Quebec.

CONCLUSIONS

Combined CRT has been the standard treatment for unresectable stage III NSCLC. In our study, a trend of better survival was seen for CRT compared with SCRT. Factors predictive of survival in patients with stage III disease treated with CRT were tumour size and nodal station. New immuno-oncology treatments after standard CRT for unresectable stage III NSCLC are the new standard in a select group of patients as defined by the eligibility criteria for the PACIFIC trial. Most patients with stage III disease would potentially be eligible for durvalumab maintenance therapy. Although the results from the study help to further contextualize the results from randomized controlled trials, the use and effectiveness of novel treatments have to be further studied in our patient population and similar real-world patient populations.

ACKNOWLEDGMENTS

This study was financially supported by AstraZeneca.

CONFLICT OF INTEREST DISCLOSURES

We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: MH and RNW are employees of AstraZeneca Canada. The remaining authors have no conflicts to disclose.

AUTHOR AFFILIATIONS

*Peter Brojde Lung Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, QC; †AstraZeneca Canada, Mississauga, ON.

REFERENCES

1. Brenner DR, Weir HK, Demers AA, et al. Projected estimates of cancer in Canada in 2020. CMAJ 2020;192:E199–205.
2. Quebec Cancer Foundation (FQC). Facts and statistics about cancer [Web page]. Montreal, QC: FQC; 2020. [Available online at: https://fqc.qc.ca/en/information/the-cancer/statistics; cited 20 April 2020]
3. Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society; 2019.
4. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer–Verlag; 2009.
5. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:138–55.
6. Canadian Partnership Against Cancer (CPAC). Cancer Stage in Performance Measurement: A First Look. A System Performance Spotlight Report. Toronto, ON: CPAC; 2015.
7. Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007. *Thorax* 2013;68:551–64.

8. Canadian Cancer Society. Lung cancer. Toronto, ON: Canadian Cancer Society; 2018. [Available online at: http://www.cancer.ca/en/cancer-information/cancer-type/lung/lung-cancer/?region=on; cited 20 April 2020]

9. Cheema PK, Rothenstein J, Melosky B, Braide A, Hirsh V. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. *Curr Oncol* 2019;26:37–42.

10. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol* 2010;28:2181–90.

11. AstraZeneca. First and Only Immuno-Oncology Treatment, Imfinzi (durvalumab), for Stage III, Unresectable Non–Small Cell Lung Cancer Now Approved in Canada (online news release). Mississauga, ON: Cision Canada Inc.; 2018. [Available at: https://www.newswire.ca/news-releases/first-and-only-immuno-oncology-treatment-imfinzi-durvalumab-for-stage-iii-unresectable-non-small-cell-lung-cancer-now-approved-in-canada-682157151.html; cited 11 September 2020]

12. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med* 2018;379:2342–50.

13. Gray JE, Villegas AE, Daniel DB, et al. Three-year overall survival update from the PACIFIC trial (abstract 8526). *J Clin Oncol* 2019;37:. [Available online at: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8526; cited 22 August 2020]

14. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. *J Clin Oncol* 2008;26:5755–60.

15. Hirsh V, Soulieres D, Duclos M, et al. Phase III multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non–small cell lung cancer. *J Thorac Oncol* 2007;2:927–32.

16. Rodrigues G, Choy H, Bradley J, et al. Definitive radiation therapy in locally advanced non–small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. *Pract Radiat Oncol* 2015;5:141–8.

17. Rodrigues G, Choy H, Bradley J, et al. Adjuvant radiation therapy in locally advanced non–small cell lung cancer: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline. *Pract Radiat Oncol* 2015;5:149–55.

18. Canadian Cancer Statistics Advisory Committee. *Canadian Cancer Statistics: A 2018 Special Report on Cancer Incidence by Stage.* Toronto, ON: Canadian Cancer Society; 2018.

19. Vinod SK, Wai E, Alexander C, Tyldesley S, Murray N. Stage III non–small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada. *J Thorac Oncol* 2012;7:1155–63.

20. Alberta Health Services (AHS). *Small Cell Lung Cancer: Limited Stage.* Clinical practice guideline LU-006. Edmonton, AB: AHS; 2012.

21. Yusuf D, Walton R, Hurry M, Cheung W. Treatment patterns and outcomes of stage III non–small cell lung cancer (NSCLC): real world evidence of how our patients fare [abstract P1.15-34]. *J Thorac Oncol* 2018;13(suppl):S262.

22. Seung SJ, Hurry M, Walton R, Evans W. Real world treatment patterns and survival of stage IV non–small cell lung cancer (NSCLC) in Ontario, Canada [abstract P1.15-28]. *J Thorac Oncol* 2018;13(suppl):S624.

23. Okawara G, Mackay J, Evans W, et al. on behalf of the Lung Cancer Disease Site Group. *Management of Unresected Stage III Non–Small-Cell Lung Cancer: A Clinical Practice Guideline.* Evidence-based series 7-3. Toronto, ON: Cancer Care Ontario; 2005.

24. Vinod S, Oar A, Gabriel G, Shafiq J, Barton M, Delaney J. Has lung cancer radiotherapy utilisation changed over time in New South Wales, Australia? [abstract P1.15-25]. *J Thorac Oncol* 2018;13(suppl):S622.

25. Swaminath A, Vella ET, Ramchandar K, et al. on behalf of the Lung Cancer Disease Site Group. *Treatment of Patients with Stage III (N2 or N3) Non–Small Cell Lung Cancer.* Toronto, ON: Cancer Care Ontario; 2017.

26. Swenson WM. Sample selection bias in clinical research. *Psychosomatics* 1980;21:291–2.

27. Tada T, Minakuchi K, Matsui K, Kin H, Nishiguchi T, Fukuda H. A single institutional subset analysis of the WILCG study comparing concurrent and sequential chemoradiotherapy for stage III non–small cell lung cancer. *Radiat Med* 2004;22:163–7.

28. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non–small cell lung cancer: randomized phase III trial NCI 9410. *J Natl Cancer Inst* 2011;103:1452–60.

29. Souza MC, Cruz OG, Vasconcelos AG. Factors associated with disease-specific survival of patients with non–small cell lung cancer. *J Bras Pneumol* 2016;42:317–25.

30. Sakaguchi T, Ito K, Furuhashi K, et al. Patients with unresectable stage III non–small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria. *Respir Investig* 2019;57:466–71.

31. Yilmaz U, Ozdemir O, Yilmaz U. Comparison of seventh TNM and eighth TNM staging system in stage III non–small cell lung cancer patients treated with concurrent chemoradiotherapy. *Curr Probl Cancer* 2019;43:33–42.